drugset / Trial / NCT06419686

The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals

NCT06419686

Phase 1 Unknown 10 enrolled University Hospital, Gentofte, Copenhagen
RandomizedCrossoverTriple-blindBasic science

Summary

The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10 healthy male participants. Each participant will undergo four separate study days in randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine. The primary objective of the study is to find out whether intravenous administration of the naturally occuring gut hormone GIP and the amino acid alanine, separately and combined, results in additive or synergistic glucagonotropic effects during euglycaemic conditions in healthy participants. Secondary objectives are to disclose the effect of the abovementioned interventions on insulin secretion and circulating levels of total and individual amino acids.

Timeline

Start
2024-01-01
Primary completion
2024-05
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GIP Unknown 4 unknown Intravenous
Subject alanine Unknown 28 unknown Intravenous

Indications

No indication recorded.